Evidence map›Paper›PMID 31443207›Full record

ArticleJournal of clinical medicine2019

Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects.

Nicolas Vuilleumier, Sabrina Pagano, Fabrizio Montecucco, Alessandra Quercioli, Thomas H Schindler, François Mach, Eleonora Cipollari, Nicoletta Ronda, Elda Favari

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Nicolas VuilleumierDivision of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, 1211 Geneva, Switzerland.
Sabrina PaganoDivision of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, 1211 Geneva, Switzerland. Sabrina.Pagano@hcuge.ch.ORCID 0000-0001-7075-1182
Fabrizio MontecuccoFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.ORCID 0000-0003-0823-8729
Alessandra QuercioliDivision of Cardiology, "SS. Antonio e Biagio e Cesare Arrigo" Hospital, 6 via Venezia 16, 15121 Alessandria, Italy.
Thomas H SchindlerDivision of Nuclear Medicine-Cardiovascular Section, Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, JHOC 3225, 601 N. Caroline Street, Baltimore, MD 21287, USA.ORCID 0000-0002-2141-7716
François MachDivision of Cardiology, Cardiology Center, Geneva University Hospital, 1211 Geneva, Switzerland.
Eleonora CipollariDepartment of Food and Drug, University of Parma, Parco Area delle Scienze, 43124 Parma 27/A, Italy.
Nicoletta RondaDepartment of Food and Drug, University of Parma, Parco Area delle Scienze, 43124 Parma 27/A, Italy.
Elda FavariDepartment of Food and Drug, University of Parma, Parco Area delle Scienze, 43124 Parma 27/A, Italy.
University of Parma · ITUniversity of Geneva · CHAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITJohns Hopkins University · USOspedale Policlinico San Martino · ITUniversity Hospital of Geneva · CH

Funding

Fondation Centre de Recherches Médicales Carlos et Elsie de Reuter 315112Fondation Leenaards 3698Swiss National Foundation 310030-163335
6 · The paper itself

Abstract

aimsTo explore the associations between cholesterol efflux capacity (CEC), coronary artery calcium (CAC) score, Framingham risk score (FRS), and antibodies against apolipoproteinA-1 (anti-apoA-1 IgG) in healthy and obese subjects (OS). METHODS AND

resultsABCA1-, ABCG1-, passive diffusion (PD)-CEC and anti-apoA-1 IgG were measured in sera from 34 controls and 35 OS who underwent CAC score determination by chest computed tomography. Anti-apoA-1 IgG ability to modulate CEC and macrophage cholesterol content (MCC) was tested in vitro. Controls and OS displayed similar ABCG1-, ABCA1-, PD-CEC, CAC and FRS scores. Logistic regression analyses indicated that FRS was the only significant predictor of CAC lesion. Overall, anti-apoA-1 IgG were significantly correlated with ABCA1-CEC (

conclusionsWe report a paradoxical positive association between ABCA1-CEC and the CAC score, with the latter being inversely associated with PD in OS. Corroborating our clinical observations, anti-apoA-1 IgG enhanced ABCA1 while repressing PD-CEC, leading to MCC increase in vitro. These results indicate that anti-apoA-1 IgG have the potential to interfere with CEC and macrophage lipid metabolism, and may underpin paradoxical associations between ABCA1-CEC and cardiovascular risk.

Indexed as

anti-apoA-1 IgGautoantibodiescholesterol efflux capacitycoronary artery calcium scoreobesity

Identifiers

PMID31443207
PMCPMC6722652
OpenAlexW2968841225

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.